Clinical Trial Update: Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ruxolitinib with pemetrexed/cisplatin in non-small cell lung cancer has been terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: NSCLC (Non-small Cell Lung Carcinoma) | Phase 2 | Status: TERMINATED | Results posted: 2017-06-14